Di Tanna, Gian Luca http://orcid.org/0000-0002-5470-3567
Urbich, Michael
Wirtz, Heidi S.
Potrata, Barbara
Heisen, Marieke
Bennison, Craig
Brazier, John
Globe, Gary
Funding for this research was provided by:
Amgen
Article History
Accepted: 10 November 2020
First Online: 30 November 2020
Declarations
:
: This work was funded by Amgen Inc. Pharmerit - an OPEN Health company commissioned by Amgen Inc. to carry out the systematic review
: Michael Urbich, Gary Globe, and Heidi S. Wirtz are employees of Amgen and hold corporate stock in Amgen. Heidi S. Wirtz also holds corporate stock in Teva Pharmaceutical Industries Ltd. Barvara Potrata, Marieke Heisen, and Craig Bennison report funding from Amgen Inc. to Pharmerit - an OPEN Health company, during the conduct of the study, and employment from Pharmerit - an OPEN Health company, outside the submitted work. Gian Luca Di Tanna was an employee of Amgen until February 2019. He received an honorarium from Amgen during the conduct of the study for providing methodological support. John Brazier has no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: All data generated or analyzed during this study are included in this published article (and its supplementary information files).
: Not applicable.
: All co-authors contributed to the design, data collection, analysis, and interpretation.